Spectral Medical Inc.
TSX:EDT.TOMedical - Diagnostics & Research
-$0.02 today
- Market cap
- $306.00M
- Beta
- 0.23
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$0.13
Volume 0.02M
Average 0.06M
EDT.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Spectral Medical Inc.TSX: EDT.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -CA$3.32M, compared with -CA$11.46M a year earlier. Trailing-twelve-month EBITDA was -CA$35.21M.
Context
- EBITDA amounted to 468.3% of revenue in FY2025, down 55.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of CA$3.06M (+126.8%) for the fiscal year ending Dec 2026, a step up from the +4.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -CA$3.32M-44.0% QoQ
- Last fiscal yearDec 2025
- -CA$11.44M+4.4% YoY
- LTMMar 2026
- -CA$35.21M-81.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +71.0% | -133.6% | -204.6 pp |
| 1 year | +4.4% | +126.8% | +122.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
CAD · from the income statement
- Latest · FY2025
- (11.44M) CAD
- Year-over-year change
- +4.4%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.44M) | +4.4% |
| FY2024 | 2024-12-31 | (11.97M) | +14.2% |
| FY2023 | 2023-12-31 | (13.96M) | -94.4% |
| FY2022 | 2022-12-31 | (7.18M) | -12.6% |
| FY2021 | 2021-12-31 | (6.38M) | — |
EBITDA vs competitors
How EDT.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -81.6% is the 7th highest of 8, against a peer median of -1.2%.
- EBITDA amounts to 1275.3% of revenue for EDT.TO, versus a peer median of 19.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $25.12M USD | +96.0% | +26.0% | 49.3% | |
| LTM Mar 2026 | CA$12.62M CAD | -1.2% | — | 19.0% | |
| LTM Mar 2026 | CA$9.82M CAD | -80.9% | — | 3.1% | |
| LTM Mar 2026 | -$5.36M USD | +48.2% | — | 10.5% | |
| LTM Mar 2026 | -CA$35.21M CAD | -81.6% | — | 1275.3% | |
PRN.TOProfound Medical Corp. | LTM Mar 2026 | -$36.45M USD | -1.4% | — | 194.3% |
| LTM Mar 2026 | -$44.63M USD | -141.2% | — | — | |
| LTM Mar 2026 | -CA$63.48M CAD | +86.8% | — | 20.4% | |
| Peer median (excluding EDT.TO) | — | -1.2% | +26.0% | 19.7% | |
Competitors are the stored peer set for EDT.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2M | 1.67M | 1.6M | 2.29M | 2.44M |
| Cost of Revenue | 832K | 684K | 936K | 1.27M | 7.6M |
| Gross Profit | 1.16M | 983K | 662K | 1.02M | (5.16M) |
| Gross Margin | 58.3% | 59.0% | 41.4% | 44.5% | -211.1% |
| Research & Development | 0 | 0 | 4.68M | 3.97M | 4.33M |
| Selling, General & Admin | 7.01M | 8.64M | 11.29M | 11.62M | 11.73M |
| Operating Expenses | 7.86M | 9.43M | 12.08M | 13.02M | 6.53M |
| Depreciation & Amortization | 294K | 272K | 218K | 251K | 250K |
| EBITDA | (6.38M) | (7.18M) | (13.96M) | (11.97M) | (11.44M) |
| EBITDA Margin | -319.4% | -430.7% | -873.3% | -523.5% | -468.3% |
| Operating Income | (6.66M) | (8.45M) | (11.42M) | (12M) | (11.69M) |
| Operating Margin | -333.5% | -506.7% | -714.7% | -524.8% | -478.5% |
| Interest Income | 0 | 0 | 0 | 0 | 5.39M |
| Interest Expense | 28K | 176K | 1.33M | 3.18M | 5.16M |
| Other Income / Expenses | (40K) | 819K | (4.09M) | (3.4M) | (36M) |
| Income Before Tax | (6.96M) | (7.63M) | (15.51M) | (15.4M) | (47.69M) |
| Pre-Tax Margin | -348.6% | -457.6% | -970.4% | -673.4% | -1952.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (8.79M) | (11.28M) | (15.66M) | (15.4M) | (47.69M) |
| Net Margin | -440.1% | -676.7% | -980.1% | -673.8% | -1953.0% |
| EPS (Basic) | (0.03) | (0.04) | (0.06) | (0.05) | (0.17) |
| EPS (Diluted) | (0.03) | (0.04) | (0.06) | (0.05) | (0.17) |
| Weighted Avg Shares | 252.46M | 269.84M | 278.56M | 281.08M | 287.21M |
| Weighted Avg Shares (Diluted) | 252.46M | 269.84M | 278.56M | 281.08M | 287.21M |
Spectral Medical Inc.
TSX:EDT.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.